The roller coaster ride of the  South Asian pharma juggernaut has won encomiums from  the high priests of the global pharma community. Today South Asia is one of the rapidly growing pharma regions and many of the  developed  nations  are looking forward to investment in South Asia owing to the   promising opportunities of these regions . In fact , India, Bangladesh  and Sri Lanka are viewed as  the fastest growing pharma economies  of the world.

Ranked third  in the world in terms of volume and 14th in terms of value, India ,the leader of south Asian pharmaceutical industry, is on a high growth trajectory. The Indian pharma market is growing at a healthy 13 per cent  annually, twice that of the world market growth rate and is estimated to grow at 15 per cent  annually from 2010 to 2014.

It is expected that the Indian pharma sector will reach US$ 55 billion in the year 2020 from US$ 12.6 billion in 2009. For multinational companies the market potential is expected to grow by US$ 8 billion for selling costly drugs by the year 2015. Besides, the domestic pharma market is likely to top US$ 20 billion by the end of 2015, making India a lucrative destination for clinical trial for the global giants.

Over the last three decades, the Indian pharmaceutical industry has transformed into a world leader in the production of high quality generic drugs. With patent expiration of several key products expected soon, global demand for generic products is going to go up substantially in the next two to three years. And India, already a well established supplier of quality generics to the developed countries is poised to  emerge as the largest supplier of pharmaceuticals to the entire world. According to the estimates of Ikon, India will emerge as a leading global player holding the rank among top five  major global markets by 2020.

While its generics market is growing strong, it is also evolving into a cradle for new drugs. India's pharmaceutical industry offer a myriad of  opportunities, especially in API, outsourcing, generics and biosimilars. As one of the strongest emerging markets in the global pharma industry, India presents great opportunities for all international pharmaceutical companies to explore and benefit from.

Showcasing  India’s pharmaceutical might, CPhI India , the largest and most comprehensive pharmaceutical event in South Asia will be revisiting  India’s city of dreams, Mumbai from November 30 to December 2, 2011.

The event will be held at the Bombay Exhibition Centre  (BEC) , which is  the largest and permanent exhibition centre in the private sector in India . BEC is ideally situated along the Western Express Highway in Goregaon, within 10 minutes from airports, walking distance to train stations and a 20 minute drive from the heart of the city.

Focused on pharmaceutical ingredients, CPhI India will be joined by co-located events: P-MEC India for pharmaceutical equipment, machinery and technology; ICSE India for contract services, clinical trials; and CRO and the BioPh trail for the biopharma market.

Catering to all sectors in the pharma industry, both domestic and international, UBM Live’s cluster of India-focused events offer attendees a dedicated platform to network with key decision makers in the Indian pharmaceutical industry, connect with existing  partners and make new contacts.  It would enable them to meet  face-to-face with potential customers, stay informed about the latest industry trends and stay ahead of a constantly changing market in the largest pharmaceutical event in South Asia.

With over 25,000 attendees and more than 800 exhibitors expected, CPhI India brings together both Indian and international pharmaceutical professionals who are actively developing their business network and seeking opportunities in the emerging India market.

In 2010 the events attracted over 26,400 visitors and over 800 exhibiting companies, figures that UBM Live, the organizer  of the event expects to exceed this year. “Mirroring the increasing importance of the Indian pharmaceutical market, CPhI India and co-located events have been built around a unique programme based on consultation and feedback from visitors and exhibitors,” says Annemieke Timmers, Brand Director CPhI. “We have geared the show to deliver significant return on investment (ROI) for pharma professionals who are currently working with or looking to establish relationships with Indian pharmaceutical companies.  Our events offer direct access to a high-growth market that is estimated to generate US $13.1 billion revenue in FY 2011. Beyond the immediate projections for the market, the domestic pharmaceutical industry in India is expected to further grow at a compounded annual growth rate (CAGR) of around 15 per cent  during FY 2012-FY 2014.  Our visitors are guaranteed to benefit from strengthening current business relations and making new business connections in a market that is well equipped to scale-up to requests for products and services quickly through networks that take advantage of the latest technologies available.”

CPhI India will be attracting  a great number of high profile visitors including industry professionals from general management,marketing & sales, purchasing, production, quality control, engineering & R& D. decision - makers from the entire chemical & pharmaceutical industry searching for new products, services & deals.

The  comprehensive range of exhibitors range from manufacturers of active pharmaceutical ingredients, intermediates, excipients and natural extracts to experts in custom manufacturing and marketing services.

The CPhI India Conference Series, taking place alongside the CPhI India exhibition will be  providing  the latest information on  the key opportunities and challenges currently facing the Indian pharma industry. This unique three-day event comprises six interactive half-day seminars consisting three expert presentations and a 40-minute interactive panel debate including a networking lunch.

Introduced in 2010, the conference series programme will cover a selection of key trends and topics pertaining to the Indian and South Asian pharmaceuticals markets, including global clinical trials, global biosimilars regulations, healthcare and OTC drugs, developing difficult generics, export potential and competitive API strategies.  The conference series will feature high-level speakers from leading  companies such as Sanofi-Aventis, GlaxoSmithKline, Pfizer and Dr. Reddy’s Laboratories.

Reflecting the continued growth in the API, generics, fine chemicals and bio-pharmaceuticals industries on the Indian sub-continent, CPhI India and related pharma services events saw a 20 per cent increases in exhibitors, coupled with a five per cent  rise in attendees in 2010. The events reflected the continued growth in region’s pharmaceutical industry.

Associations like Pharmexcil, CCCMHPIE, CCPIT made their presence and support felt through large pavilions. Companies from India, China, Japan, Germany, Taiwan, USA, France, Canada, UK, Japan, Korea, Belgium, The Netherlands, Czech Republic, Italy, Israel, Singapore, Switzerland participated in the event.  The event saw 26436 visitors from India and abroad from more than18 countries.

It proved to be  a meeting of minds that were exploring every realm of business opportunity.

The event  also saw the launch of the concurrent CPhI India conference series. The conferences were divided into 12 modules, with interesting presentations followed by interactive panel discussions. Each day was interesting with four modules that featured in-depth analysis and case studies led
by a line-up of carefully selected speakers from leading pharma manufacturers as well as allied industries and had around 322 visitors.